Earnings Feed
Start Free
Home/Filings/3/0001209191-19-008289
3//SEC Filing

ARCH Venture Partners IX, LLC 3

Accession 0001209191-19-008289

CIK 0001728117other
View on SEC.govCompany Profile

Filed

Feb 6, 7:00 PM ET

Accepted

Feb 7, 7:28 PM ET

Size

24.9 KB

Accession

0001209191-19-008289

Insider Transaction Report

Form 3
Period: 2019-02-07
Gossamer Bio, Inc.GOSS
ARCH Venture Partners IX, L.P.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)
ARCH Venture Partners IX Overage, L.P.
10% Owner
Holdings

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)
ARCH Venture Fund IX, L.P.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)
ARCH Venture Fund IX Overage, L.P.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)
NELSEN ROBERT
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)
CRANDELL KEITH
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)
BYBEE CLINTON
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)
ARCH Venture Partners IX, LLC
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)

  • Series A Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (3,682,539 underlying)

  • Series B Preferred Stock

    (indirect: See footnotes)
    Exercise: $0.00→ Common Stock (345,419 underlying)
Footnotes (5)
  • [F1]Each of the 16,571,429 and 16,571,428 shares of Series A Preferred Stock held by ARCH Venture Fund IX, L.P. ("ARCH IX") and ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"), respectively, is convertible, at any time, at the holder's election, at a ratio of 4.5 to one share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, for no additional consideration, each share of Series A Preferred Stock will automatically convert at a ratio of 4.5 to one share of the Issuer's common stock. The Series A Preferred Stock has no expiration date.
  • [F2]These shares are directly held by ARCH IX. ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. As managing directors of GPLLC, each of Keith Crandell, Clinton Bybee and Robert Nelsen (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by GPLLC.
  • [F3]Each of GPLP, Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
  • [F4]These shares are directly held by ARCH Overage. ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by GPLLC.
  • [F5]Each of the 1,554,388 and 1,554,388 shares of Series B Preferred Stock held by ARCH IX and ARCH Overage, respectively, is convertible, at any time, at the holder's election, at a ratio of 4.5 to one share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, for no additional consideration, each share of Series B Preferred Stock will automatically convert at a ratio of 4.5 to one share of the Issuer's common stock. The Series B Preferred Stock has no expiration date.

Documents

2 files

Issuer

Gossamer Bio, Inc.

CIK 0001728117

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001723174

Filing Metadata

Form type
3
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 7:28 PM ET
Size
24.9 KB
View on SEC.gov